Hormonal
Gene expression changes in adipose tissue of insulin-resistant obese individuals are depot-specific, whereas AMPK activity and oxidative stress are uniform across depots.
Fat tissue is not uniform. In insulin-resistant obesity, some molecular markers (like oxidative stress) are high everywhere, but the genes being turned on or off depend on where the fat is stored (e.g., belly vs. under skin). This complexity means treatments might need to target specific fat depots or understand that 'fat' is not a single organ with a single behavior.
However, most changes in gene expression appear to be depot-specific.
Why this rating
Detailed PCR array analysis across three specific fat depots (subcutaneous, omental, epiploic) in the same subjects.
Source
Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue
X. Julia Xu et al. · Journal of Lipid Research · 2012
DOI 10.1194/jlr.p022905
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →